RPL18

Across TCGA pan-cancer cohorts, RPL18 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RPL18 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RPL18 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPL18 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where RPL18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.798	0.430	<.001	50	view →
CCRCC	OS	Median	III,IV	0.492	0.874	<.001	46	view →
LSCC	DFS	Tertile	II,III,IV	0.919	0.614	.009	12	view →
UCEC	OS	Median	All	0.984	0.916	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RPL18–LUAD (DFS)

Open the LUAD breakdown →